个人简介：中南大学湘雅基础医学院研究员、博士生导师；中南大学肿瘤研究所所长
教育部长江学者特聘教授、湖南省芙蓉学者特聘教授
研究方向：肿瘤癌变原理、肿瘤耐药机制及肿瘤干细胞研究，主要研究造血系统恶性肿瘤多发性骨髓瘤（Multiple Myeloma, MM）的癌变及耐药机制：1.利用单细胞技术探讨MM细胞起源及建立耐药过程中的克隆演进模型；2.利用转录组、微生物组和代谢组等多组学技术结合临床标本和小鼠模型探讨MM发生、发展及耐药的分子机制。
学术成就：研究成果以通讯作者发表在Cell Metabolism、Blood、Advanced Science、Nature Communications（2022，2023）、Microbiome 和 Leukemia 等期刊上；团队成果“首次从代谢失衡解析多发性骨髓瘤发病及耐药机制”入选“2023年度中国血液学十大研究进展”。于第20届国际骨髓瘤学会年会（IMS）作主题报告，并多次获得美国血液学年会（ASH）口头发言。主持国家自然科学基金委重点项目两项（项目编号：82130006、82430008）、面上项目（项目编号：81974010、81570205）、湖南省重点研发项目（项目编号：2020WK2006）和海河生态实验室创新课题（HH22KYZX0030）；参与国家重点研发计划“干细胞及转化研究”试点专项（项目编号：2018YFA0107803）。担任中国抗癌协会中西整合多发性骨髓瘤专业委员会主任委员、中国细胞生物学会青年委员、中国细胞生物学会肿瘤委员会委员和中国生理学会血液生理委员会青年委员等学术任职。
以通讯作者或第一作者发表的部分代表性论文：
1. Yang Q, Zhu Y, Jian X, Qiu Y, Zhu Y, Zhao L, He Y, An G, Qiu L, Guo J, He N, Abudumijiti H, Hu C, Chen X, Huang S, Feng X, Li X, Liu J*, Xu Y*, Zhou W*. Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma. Blood. 2025 Apr 24;145(17):1876-1889.（IF=21.1）
2. Zhu Y#, Jian X#, Chen S, An G, Jiang D, Yang Q, Zhang J, Hu J, Qiu Y, Feng X, Guo J, Chen X, Li Z, Zhou R, Hu C, He N, Shi F, Huang S, Liu H, Li X, Xie L, Zhu Y, Zhao L, Jiang Y, Li J, Wang J, Qiu L, Chen X*, Jia W*, He Y*, Zhou W*. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab. 2024 Jan 2;36(1):159-175.e8. （IF=27.7）
3. Kuang C#, Xia M#, An G, Liu C, Hu C, Zhang J, Liu Z, Meng B, Su P, Xia J, Guo J, Zhu Y, Liu X, Wu X, Shen Y, Feng X, He Y, Li J, Qiu L, Zhou J*, Zhou W*. Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma. Nat Commun. 2023 Apr 13;14(1):2093.（2023 Nat Commun Feature article in cancer）（IF=17.8）
4. Jiliang Xia*, Jingyu Zhang*,Xuan Wu,Wanqing Du,Yinghong Zhu,Xing Liu,Zhenhao Liu,Bin Meng,Jiaojiao Guo,Qin Yang, Yihui Wang, Qinglin Wang,Xiangling Feng,Guoxiang Xie,Yi Shen,Yanjuan He, Juanjuan Xiang, Minghua Wu, Gang An, Lugui Qiu, Wei Jia, Wen Zhou# Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance[J] Nat Commun 2022 Jul 11;13(1):4007. PMID: 35817773 （IF=17.8）
5. Feng X*, Guo J*, An G, Wu Y, Liu Z, Meng B, He N, Zhao X, Chen S, Zhu Y, Xia J, Li X, Yu Z, Li R, Ren G, Chen J, Wu M, He Y, Qiu L, Zhou J, Zhou W#. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma[J]. Adv Sci (Weinh). 2022 Mar;9(9):e2104491 PMID: 35088582（IF=16.8）
6. Xingxing Jian*, Yinghong Zhu*, Jian Ouyang, Qian Lei, Jiliang Xia, Jingyu Zhang, Jiaojiao Guo, Jinuo Wang, Jinchao Lin, Mingming Su, Yongjun Guan, Guancheng Li, Minghua Wu, Lugui Qiu, Jian Li, Juanjuan Xiang, Lu Xie, Lugui Qiu,Wei Jia and Wen Zhou#. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria[J]. Microbiome, 2020, 8(1). PMCID: PMC7257554（IF=14.6）
7. Jiliang Xia*, Yanjuan He*, Bin Meng, Shilian Chen, Jingyu Zhang, Xuan Wu, Yinghong Zhu, Yi Shen, Xiangling Feng, Yongjun Guan, Chunmei Kuang, Jiaojiao Guo, Qian Lei, Yangbowen Wu, Gang An, Guancheng Li, Lugui Qiu, Fenghuang Zhan and Wen Zhou#. NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma[J]. Mol Oncol. 2020;14(4): 763-778. PMCID: PMC7138399 （IF=6.574）
8. Yu Wang, Hongtao Wang, Jiaojiao Guo, Jie Gao, Mengge Wang, Meijuan Xia, Yuqi Wen, Pei Su, Ming Yang, Mingyao Liu, Lihong Shi, Tao Cheng, Wen Zhou# and Jiaxi Zhou#. LGR4, Not LGR5, Enhances hPSC Hematopoiesis by Facilitating Mesoderm Induction via TGF-Beta Signaling Activation[J]. Cell Reports, 2020, 31(5): 107600. PMID: 32375050 （IF=8.109）
9. Xuan Wu*, Jiliang Xia*, Jingyu Zhang, Yinghong Zhu, Yangbowen Wu, Jiaojiao Guo, Shilian Chen, Qian Lei, Bin Meng, Chunmei Kuang, Xiangling Feng, Yanjuan He, Yi Shen, Xin Li, Lugui Qiu, Guancheng Li# and Wen Zhou#. Phosphoglycerate Dehydrogenase Promotes Proliferation and Bortezomib Resistance Through Increasing Reduced Glutathione Synthesis in Multiple Myeloma[J]. British Journal of Haematology. 2020;16(503). PMID: 32037523（IF=5.518）
10. Meirong Zang*, Jiaojiao Guo*, Lanting Liu*, Fengyan Jin*, Xiangling Feng, Gang An , Xiaoqi Qin, Yangbowen Wu , Qian Lei, Bin Meng , Yinghong Zhu, Yongjun Guan , Shuhui Deng, Mu Hao , Yan Xu, Dehui Zou , Minghua Wu , Lugui Qiu# and Wen Zhou#. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s[J]. Oncogenesis. 2020;9(3):31. PMCID: PMC7058164 （IF=6.119）
11. Yu Qin*, Shuaishuai Zhang*, Shuhui Deng*, Gang An, Xiaoqi Qin, Fei Li,Yan Xu, Mu Hao, Yijun Yang , Wen Zhou# (co-correpondence), Hong Chang# , Lugui Qiu#. Epigenetic silencing 1 of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma[J].Leukemia. 2017;31(5):1123-1135. PMID: 27857131（IF 12.1）
12. Zhou W*, Yang Y*, Gu Z,Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J#, ZhanF#. ALDH1 Activity identifies tumor initiating cells and links to chromosomal instability signatures in multiple myeloma[J]. Leukemia. 2014;28(5):1155-8. PMID:24365790（IF 12.1）
13. Zhou W*, Yang Y*, Xia J*, Wang H*, Salama ME,Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D,Tricot G#, Zhan F#. NEK2 induces drug resistance mainly through activation ofefflux drug pumps and is associated with poor prognosis in myeloma and other cancers[J]. Cancer Cell. 2013;23(1):48-62. PMID:23328480 （Article featured by Nature reviews drug discovery, recommend toF1000 prime, reviewed by Nature Reviews cancer, Blood et al.）（IF 24.7）